Targeted Tolerance Induction in Pemphigus Vulgaris: A Synthesis of Phase I Clinical and Preclinical Evidence for TPM203 Nanoparticles

Highlights

• TPM203, an innovative nanoparticle platform, demonstrates a favorable safety profile with no serious adverse events in its first-in-human Phase I trial.
• The therapy utilizes liver sinusoidal endothelial cells (LSECs) to promote antigen-specific tolerance by delivering immunodominant desmoglein 3 (Dsg3) peptides.
• Pharmacodynamic results reveal a significant increase in regulatory T (Treg) cells and a reduction in Th17.1 and memory B-cell subsets.
• Preclinical and early clinical data suggest a reduction in anti-Dsg3 IgG-induced keratinocyte dissociation, indicating potential for disease modification.

Background